Victory Capital Management Inc. Sells 7,441 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Victory Capital Management Inc. lessened its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 113,701 shares of the biopharmaceutical company’s stock after selling 7,441 shares during the period. Victory Capital Management Inc. owned 0.05% of Alexion Pharmaceuticals worth $13,597,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Grandfield & Dodd LLC lifted its position in shares of Alexion Pharmaceuticals by 12.6% during the 3rd quarter. Grandfield & Dodd LLC now owns 3,785 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 425 shares during the last quarter. Bender Robert & Associates lifted its position in shares of Alexion Pharmaceuticals by 1.3% during the 4th quarter. Bender Robert & Associates now owns 32,873 shares of the biopharmaceutical company’s stock valued at $3,931,000 after buying an additional 430 shares during the last quarter. Raymond James Trust N.A. lifted its position in shares of Alexion Pharmaceuticals by 27.2% during the 3rd quarter. Raymond James Trust N.A. now owns 2,132 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 456 shares during the last quarter. BB&T Corp lifted its position in shares of Alexion Pharmaceuticals by 8.1% during the 3rd quarter. BB&T Corp now owns 6,171 shares of the biopharmaceutical company’s stock valued at $866,000 after buying an additional 463 shares during the last quarter. Finally, Comerica Bank lifted its position in shares of Alexion Pharmaceuticals by 0.9% during the 3rd quarter. Comerica Bank now owns 59,224 shares of the biopharmaceutical company’s stock valued at $7,569,000 after buying an additional 503 shares during the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have recently commented on ALXN shares. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Robert W. Baird raised Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 price target on the stock in a research report on Monday, December 18th. Royal Bank of Canada upped their price target on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $170.00 price objective on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $152.77.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $123.20 on Thursday. The firm has a market capitalization of $27,310.00, a PE ratio of 62.54, a price-to-earnings-growth ratio of 1.08 and a beta of 1.16. The company has a quick ratio of 2.62, a current ratio of 3.10 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 1.36% and a net margin of 3.33%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 EPS. equities analysts predict that Alexion Pharmaceuticals, Inc. will post 5.87 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 655 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the transaction, the senior vice president now directly owns 32,635 shares in the company, valued at approximately $3,826,780.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John B. Moriarty sold 3,363 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $115.70, for a total value of $389,099.10. Following the completion of the transaction, the executive vice president now owns 71,400 shares in the company, valued at $8,260,980. The disclosure for this sale can be found here. Insiders sold a total of 28,930 shares of company stock worth $3,378,199 over the last 90 days. Corporate insiders own 4.35% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Victory Capital Management Inc. Sells 7,441 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://weekherald.com/2018/02/15/victory-capital-management-inc-sells-7441-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply